After Friday’s Approx 50% Move - Your Next Profile is Coming Tonight or Early Tomorrow Morning - Info Forex 24 Hours - Daily Signal

Brand New Krypton Street Profile is Coming Tonight!

The Time to Get Ready is Now…

This little-known biotech company is backed by several exciting catalysts:

Analyst Buzz: Top analysts like Jonathan Aschoff are targeting a potential +1,546% upside, while Jason McCarthy sees +723% potential growth.

Tiny Public Float: With fewer than 2.8M shares available, this razor-thin float could lead to big swings and increased volatility.

Flying Under the Radar: Despite having a market cap under $7M, this company remains largely unnoticed by the broader market, but that might not last long.

FDA Milestones: Multiple FDA clearances have already been secured for their innovative therapies, including a promising one targeting cancer.

Take 2 Minutes Now to Connect with Us on all of Our No-Cost Platforms!

(See instructions below)

September 22, 2024

Dear Reader,

Coming off of Friday’s profile that showcased an approximate 50% move in the pre-market we need to shift our focus to another exciting sector.

Biotech and pharmaceutical firms often fit the profile of what can be called “big story” companies.

With this in mind, there’s one little-known pharma company that just came across my desk, and it needs to be on your radar early tomorrow morning.

(We are announcing coverage tonight around 8:00 PM EST)

In fact, recent analyst coverage suggests 1,546% in potential upside for this under the radar company.

This under-the-radar biotech is gaining attention for several key reasons:

Analyst Buzz: Top analysts have set ambitious targets—Jonathan Aschoff reiterates a $40 target (+1,546% potential upside), while Jason McCarthy sets a $20 target (+723% upside). With shares currently around $2.43, there's significant growth potential.

Razor-Thin Float: Less than 2.8M shares available in the public float means big swings and increased volatility could be on the horizon, making it a company to watch closely.

Unnoticed by the Broader Market: With a market cap under $7M, this biotech remains under the radar, but that may change if more eyes start looking its way.

Groundbreaking Phase 2 Trial: Their Phase 2 glioblastoma trial, conducted by Northwestern University and backed by NIH, is advancing innovative therapies for this aggressive brain cancer.

Next-Generation Cancer Therapeutics: The company is developing a new treatment designed to tackle relapsed AML and soft tissue sarcoma lung metastases, addressing areas where current therapies fall short.

Pivotal Phase 3 Clinical Trials: Their trial, a critical Phase 3 study, is progressing to potentially bring a new solution for relapsed AML, driven by promising earlier-phase results.

FDA Milestones: With multiple FDA clearances for their groundbreaking therapies, this biotech is advancing through crucial clinical phases under FDA guidance.

Get ready now because this next profile is coming directly to you by 8:00PM EST tonight or by 9:30 AM tomorrow morning!

However, you’ll probably want to be one of the first to get this one on your watchlist, so I suggest you connect with us on our no-cost SMS and Chat Platforms to get a head of the crowd.

To make sure you're among the first to receive this game-changing profile, take 2 minutes now to connect with us on all of our no-cost platforms.

If you haven't already, please take a moment to set up these platforms now:

Click here for SMS: